Hoth Therapeutics, a biopharmaceutical company based in New York, has announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for HT-001, a
Hoth Therapeutics, a biopharmaceutical company based in New York, has announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for HT-001, a